Cardiff Oncology (CRDF) Q4 2025 earnings summary

Executive summary

• Advanced lead program onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) with strong Phase 2 results and plans for registrational development in 2026.

• Leadership transition to support late-stage clinical development, including interim CEO appointment and search for permanent CEO and CFO.

• Presented positive clinical data in chronic myelomonocytic leukemia (CMML), showing preliminary efficacy and good tolerability.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $58.3 million as of December 31, 2025, expected to fund operations into Q1 2027.

• Total operating expenses for 2025 were $49.6 million, up slightly from $49.3 million in 2024, mainly due to higher SG&A expenses.

• Net loss attributable to common stockholders was $45.9 million for 2025, compared to $45.5 million in 2024.

• Net loss per share improved to $(0.69) from $(0.95) year-over-year.

Outlook and guidance

• Plans to advance 30 mg onvansertib + FOLFIRI/bev into registrational development, with detailed data and FDA discussions expected in H1 2026.

• Cash runway projected to last into the first quarter of 2027 based on current plans.